Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/50 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/243149PROTEIN COVARIANCE NETWORKS REVEAL INTERACTIONS IMPORTANT TO THE EMERGENCE OF SARS CORONAVIRUSES AS HUMAN PATHOGENS
WO 02.12.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/034753 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor MEKALANOS, John, J.
The methods and compositions provided herein, relate in part, to the discovery of conserved interactions between amino acid residues in all proteins encoded by SARS-CoV-related viruses. Accordingly, pairs and networks of residue variants that exhibited statistically high frequencies of covariance with each other can be used as a new computational approach (Covariance-based Phylogeny Analysis) for understanding viral evolution and adaptation. Provided herein is evidence that the evolutionary processes that converted a bat virus into a human pathogen occurred through recombination with other viruses in combination with new adaptive mutations important for entry into human cells.
2.WO/2022/047575MODIFIED CORONAVIRUS STRUCTURAL PROTEIN
WO 10.03.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CA2021/051201 Applicant MEDICAGO INC. Inventor LAVOIE, Pierre-Olivier
Modified coronaviras spike (S)-protein, virus-like particle (VLPs) comprising the modified S protein and nucleic acids encoding modified S protein are provided. Methods for modified S-protein and VLP production in a host or host cell are also described. The modified S-protein may comprise a transmembrane domain (TM) or portion of a TM, and a cytosolic tail (CT) or of a CT, wherein the CT or portion of the CT is derived from an influenza hemagglutinin (HA) protein and wherein the TM or portion of the TM is heterologous to the CT or portion of the CT. In addition a method for inducing immunity to a coronaviras infection in a subject, comprising administering a composition comprising the modified coronaviras (S)-protein or VLP to the subject is described.
3.WO/2021/198963VECTORS FOR PRODUCING VIRUS-LIKE PARTICLES AND USES THEREOF
WO 07.10.2021
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/IB2021/052710 Applicant MEDIPHAGE BIOCEUTICALS, INC. Inventor SLAVCEV, Roderick
The present disclosure provides expression vectors and bacterial sequence-free vectors, such as ministring DNA (msDNA), for producing virus-like particles (VLPs) as well as compositions and methods thereof. In some aspects, the methods include treating viral infections in subjects with the vectors, compositions, and VLPs.
4.WO/2021/209275PARTICLES, DNA & RNA
WO 21.10.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/EP2021/058821 Applicant NOVOSCOPE IP LIMITED Inventor CLUBE, Jasper
The invention provides competitive particles, such as virus-like particles, RNAs and DNAs for the treatment or prevention of viral infections and methods of using such particles for treating or preventing or reducing the risk of viral infections (or symptoms thereof) in a subject, such as a human or animal subject. For example, the method herein is a method of reducing or reducing the establishment of a zoonotic population of a virus in an animal, such as a livestock or wild animal (eg, a bat, camelid or a Pholidota (eg, a pangolin)).
5.WO/2022/150293CORONAVIRUS REPLICON DELIVERY PARTICLES AND METHODS OF USE THEREOF
WO 14.07.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/US2022/011115 Applicant THE ROCKEFELLER UNIVERSITY Inventor RICE, Charles
This disclosure provides RNA replicons (e.g., SARS-CoV-2 RNA replicons) that can be trans-packaged for single-cycle delivery into a wide array of cell types and recapitulate all major enzymatic activities of intracellular viral replication. As a low-containment platform, the disclosed RNA replicons are broadly amenable to molecular virology studies and drug development screening efforts.
6.WO/2021/207213METHODS TO PREVENT SARS-COV-2 INFECTION AND TREAT COVID-19
WO 14.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/025980 Applicant UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED Inventor OSTROV, David A.
Methods of preventing or treating infection by a SARS-CoV-related betacoronavirus are described. The methods include administering to a patient at risk of being infected by a SARS-CoV-related betacoronavirus or suffering from SARS-CoV-related betacoronavirus-related illness a small molecule drug and/or an antibody that binds to the ACE2-SARS interaction domain of either ACE2 or SARS-CoV-2 spike protein. Also described are vaccines comprising S-protein polypeptides corresponding to the ACE-2 interaction domain.
7.WO/2021/203397ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF
WO 14.10.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CN2020/084097 Applicant TSB THERAPEUTICS (BEIJING) CO. LTD. Inventor ZHANG, Zheng
Provided herein are novel anti-SARS-COV-2 antibodies or antigen binding fragments thereof, pharmaceutical composition and kits comprising the same, and the uses thereof.
8.WO/2022/051859PSEUDOTYPED RETROVIRAL PARTICLES FOR INDUCING IMMUNITY AGAINST CORONAVIRUS INFECTIONS
WO 17.03.2022
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CA2021/051254 Applicant CARUSO, Manuel Inventor CARUSO, Manuel
The present disclosure generally relates to recombinant, pseudotyped virus-like particles (VLPs) derived from a retroviral vector and having a Coronavirus spike (S) protein or an immunogenic portion thereof on the viral envelope, as well as to compositions thereof, and methods of use thereof for the prevention or treatment of Coronavirus infections in a subject.
9.WO/2017/046801CORONAVIRUSES EPITOPE-BASED VACCINES
WO 23.03.2017
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No PCT/IL2016/051029 Applicant RAMOT AT TEL-AVIV UNIVERSITY LTD. Inventor GERSHONI, Jonathan
The present invention provides polypeptides derived from the coronaviruses (Co Vs) Spike protein (S) characterized by high affinity and specificity the S receptor and its neutralizing antibodies. The invention further provides compositions and vaccines, and vaccine-based therapies targeting Co Vs, and SARS and MERS viruses in particular.
10.3156456THE USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 FOR REVACCINATION OF POPULATION (VARIANTS)
CA 27.07.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No 3156456 Applicant FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION Inventor ZUBKOVA, OLGA VADIMOVNA
The group of inventions relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with El and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. In addition an agent is used, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with El and E3 sites deleted from the genome, and the site 0RF6-Ad26 is substituted for 0RF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, or containing only component 2. Furthermore, an agent is used, such agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with El and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. The group of invention enables to create safe and efficacious agents providing extension of postvaccinal immunity against virus SARS-CV-2, and is intended for revaccination of population against the diseases caused by severe acute respiratory syndrome virus SARS-CoV-2.